Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LBH 589 Clear all
Terminated Phase 1 Interventional

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

NCT05324501
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
MTX110, Programmable pump and catheter system
Drug · Device
Lead sponsor
Biodexa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 2 Interventional Results available

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

NCT00594230
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Panobinostat
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Fort Myers, Florida • Gainesville, Georgia • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

NCT01056601
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Bortezomib, Panobinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Phase II Trial of LBH589 in Refractory Colorectal Cancer

NCT00690677
View directory record Official record
Conditions
Colorectal Cancer
Interventions
LBH589
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

NCT00663832
View directory record Official record
Conditions
Prostate Cancer
Interventions
LBH589 (i.v. panobinostat)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Rockville, Maryland • Detroit, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Trial of LBH589 in Metastatic Thyroid Cancer

NCT01013597
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
LBH589
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

NCT01802879
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

NCT01238965
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
panobinostat, fluorouracil, leucovorin calcium, biopsy, reverse transcriptase-polymerase chain reaction, western blotting, laboratory biomarker analysis, gene expression analysis, RNA analysis, polymorphism analysis
Drug · Procedure · Genetic + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

NCT01324635
View directory record Official record
Conditions
Recurrent Glioma, High-grade Meningioma, Brain Metastasis
Interventions
Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment, Stereotactic radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions
PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat - LBH589
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01023308
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat, Bortezomib, Dexamethasone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Concord, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Panobinostat (LBH589)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

NCT00493766
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

NCT01693601
View directory record Official record
Conditions
Myelofibrosis
Interventions
Panobinostat, Ruxolitinib
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

NCT00925132
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Temozolomide, Decitabine, Panobinostat
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

NCT00532675
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LBH589, Lenalidomide
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

NCT00777049
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Panobinostat, Bicalutamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

NCT01034163
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Panobinostat, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

NCT00997399
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
panobinostat (LBH589)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

NCT00878904
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, panobinostat, gene expression analysis, protein expression analysis, western blotting, immunologic technique, laboratory biomarker analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT04956302
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Panobinostat Lactate
Drug
Lead sponsor
Abdullah Khan
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT02506959
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 13, 2026, 5:51 PM EDT